Join
Live feed
·
INSIDERFilingvia Quantisnow
Nektar Therapeutics logo

Chief R&D Officer Zalevsky Jonathan sold $336,212 worth of shares (5,538 units at $60.71) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 15,437 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
NKTR· Nektar Therapeutics
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NKTR (Nektar Therapeutics) and more on Quantisnow.